Supernus Pharmaceuticals | SUPN - Ebitda


Supernus Pharmaceuticals reported $31.6M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
ANI Pharmaceuticals USD 71.6M 6.69M Jun/2026
Aurora Cannabis CAD 3.7M 14.78M Mar/2026
Bristol-Myers Squibb USD 5.09B 842M Jun/2026
Canopy Growth CAD -137M 134.13M Mar/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD -49M 53.2M Mar/2026
Eisai JPY 34.15B 34.48B Jun/2026
Eli Lilly USD 12.99B 2.7B Jun/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Pacira USD 48.67M 8.43M Jun/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Supernus Pharmaceuticals USD 31.6M 2.37M Jun/2026
United Therapeutics USD 355M 11.1M Jun/2026
Xeris Pharmaceuticals USD 12.33M 12.76M Mar/2026